Management of impulse control disorders in Parkinson's disease

Current Treatment Options in Neurology

Volumn 9, Issue 3, 2007, Pages 189-197

  Galpern, Wendy R ^b   Stacy, Mark ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYPROTERONE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; SERTRALINE; VALPROIC ACID;

AGRANULOCYTOSIS; BRAIN DEPTH STIMULATION; COMBINATION CHEMOTHERAPY; COMPULSION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LOW DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PSYCHOSOCIAL CARE; REVIEW; SIDE EFFECT; SUBTHALAMIC NUCLEUS;

EID: 34248329146     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938408     Document Type: Review

References (38)

1. Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 1971, 218:1915-1920.
2. Uitti RJ, Tanner CM, Rajput AH, et al.: Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989, 12:375-383.
3. Giovannoni G, O'Sullivan JD, Turner K, et al.: Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000, 68:423-428.
4. Evans AH, Lees AJ: Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004, 17:393-398.
5. Weintraub D, Siderowf AD, Potenza MN, et al.: Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006, 63:969-973.
6. Voon V, Hassan K, Zurowski M, et al.: Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006, 67:1254-1257.
7. Pontone G, Williams JR, Bassett SS, Marsh L: Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006, 67:1258-1261.
8. Kurlan R: Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004, 19:433-437.
9. Driver-Dunckley E, Samanta J, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003, 61:422-423.
10. Dodd ML, Klos KJ, Bower JH, et al.: Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005, 62:1377-1381.
11. Bearn J, Evans A, Kelleher M, et al.: Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004, 76:305-310.
12. Pezzella FR, Colosimo C, Vanacore N, et al.: Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005, 20:77-81.
13. Evans AH, Lawrence AD, Potts J, et al.: Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005, 65:1570-1574.
14. Imamura A, Uitti RJ, Wszolek ZK: Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord 2006, 12:506-508.
15. Voon V, Hassan K, Zurowski M, et al.: Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006, 66:1750-1752.
16. Molina JA, Sainz-Artiga MJ, Fraile A, et al.: Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000, 15:869-872.
17. Lu C, Bharmal A, Suchowersky O: Gambling and Parkinson disease. Arch Neurol 2006, 63:298.
18. Aarsland D, Alves G, Larsen JP: Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. Adv Neurol 2005, 96:56-64.
19. Klos KJ, Bower JH, Josephs KA, et al.: Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005, 11:381-386.
20. Nirenberg MJ, Waters C: Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006, 21524-529.
21. Friedman JH: Punding on levodopa. Biol Psychiatry 1994, 36:350-351.
22. Fernandez HH, Friedman JH: Punding on L-dopa. Mov Disord 1999, 14:836-838.
23. Miwa H, Kondo T: Increased writing activity in Parkinson's disease: a punding-like behavior? Parkinsonism Relat Disord 2005, 11:323-325.
24. Evans AH, Katzenschlager R, Paviour D, et al.: Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004, 19:397-405.
25. Potenza MN, Steinberg MA, Skudlarski P, et al.: Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003, 60:828-836.
26. Reuter J, Raedler T, Rose M, et al.: Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005, 8:147-148.
27. Voon V: Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord 2004, 19:367-370.
28. Avanzi M, Uber E, Bonfa F: Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 2004, 25:98-101.
29. Avanzi M, Baratti M, Cabrini S, et al.: Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006, 21:2068-2072.
30. Ivanco LS, Bohnen NI: Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther 2005, 12:467-468.
31. Fernandez HH, Durso R: Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 1998, 13:597-598.
32. Seedat S, Kesler S, Niehaus DJ, Stein DJ: Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000, 11:185-186.
33. Gschwandtner U, Aston J, Renaud S, Fuhr P: Pathologic gambling in patients with Parkinson's disease. Clin Neuro-pharmacol 2001, 24:170-172.
34. Witjas T, Baunez C, Henry JM, et al.: Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005, 20:1052-1055.
35. Bandini F, Primavera A, Pizzorno M, Cocito L: Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2006, In press.
36. Ardouin C, Voon V, Worbe Y, et al.: Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006, 21:1941-1946.
37. Tippmann-Peikert M, Park JG, Boeve BF, et al.: Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68:301-303.
38. Grant JE, Potenza MN: Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004, 16:27-34.